2014Chinese Journal of Clinical NeurosciencesRequires access

Direct Central Nervous System Therapeutic Effects of Fingolimod in Multiple Sclerosis

Tan Qian

Open publisher page 0 citations

Abstract

Multiple sclerosis(MS) is a chronic inflammatory demyelinating disease of the central nervous system(CNS), which has not be cured yet. Fingolimod(FTY720) is a newly oral disease-modifying therapy approved for RRMS. The mechanism of action of fingolimod in MS has primarily been considered as selectively retaining autoreactive lymphocytes in lymph nodes to reduce damaging infiltration into the CNS. However,emerging evidence indicated that fingolimod has direct effects in the CNS in MS, which may be more important than the former. This review focused on the advances in direct CNS therapeutic effects of fingolimod in MS.

About this research paper

What this paper is about

Multiple sclerosis(MS) is a chronic inflammatory demyelinating disease of the central nervous system(CNS), which has not be cured yet. Fingolimod(FTY720) is a newly oral disease-modifying therapy approved for RRMS. The mechanism of action of fingolimod in MS has primarily been considered as selectively retaining autoreactive lymphocytes in lymph nodes to reduce damaging infiltration into the CNS. However,emerging evidence indicated that fingolimod has direct effects in the CNS in MS, which may be more important than the former. This review focused on the advances in direct CNS therapeutic effects of fingolimod in MS.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Multiple sclerosis(MS) is a chronic inflammatory demyelinating disease of the central nervous system(CNS), which has not be cured yet. Fingolimod(FTY720) is a newly oral disease-modifying therapy approved for RRMS. The mechanism of action of fingolimod in MS has primarily been considered as selectively retaining autoreactive lymphocytes in lymph nodes to reduce damaging infiltration into the CNS. However,emerging evidence indicated that fingolimod has direct effects in the CNS in MS, which may be more important than the former. This review focused on the advances in direct CNS therapeutic effects of fingolimod in MS.

Key concepts: Fingolimod, Multiple sclerosis, Central nervous system, Medicine, Demyelinating Disorder, Neuroscience, Immunology, Biology

Related papers

Back to paper searchBrowse research topicsOriginal source
Direct Central Nervous System Therapeutic Effects of Fingolimod in Multiple Sclerosis — Research Paper | ScholarLens